Rationale and protocol of MetNET-2 trial: Lanreotide Autogel plus metformin in advanced gastrointestinal or lung neuroendocrine tumors

Future Oncology Ahead of Print.


from Cancer via ola Kala on Inoreader http://ift.tt/2rYlsfg
via IFTTT